Ozempic Boom Is an Opportunity for Health Insurers

Norge Nyheter Nyheter

Ozempic Boom Is an Opportunity for Health Insurers
Norge Siste Nytt,Norge Overskrifter
  • 📰 WSJ
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 63%

Diabetes drugs could become an effective way to treat behavioral issues and addiction. WSJ’s Daniela Hernandez breaks down the science on how they work and how they could change psychiatry forever. Photo illustration: Elizabeth Smelov

WSJ’s Daniela Hernandez breaks down the science of how diabetes drugs work—and how they could change psychiatry. Photo illustration: Elizabeth Smelovtaken by millions of Americans would be a problem for health insurers. After all, they ultimately foot the bill. But it is more complicated than that: Some insurance giants actually stand to profit from the Ozempic craze., which are used for both diabetes and obesity.

But federally supported Medicare and Medicaid still don’t cover the drugs for obesity, and much of the commercial market is self-insured. In other words, even though your insurance card says “Aetna” or “UnitedHealthcare,” those companies in some cases only act as administrators. That means employers are the ones bearing theThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law.

Vi har oppsummert denne nyheten slik at du kan lese den raskt. Er du interessert i nyhetene kan du lese hele teksten her. Les mer:

WSJ /  🏆 98. in US

Norge Siste Nytt, Norge Overskrifter

Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.

Popular use of obesity drugs like Ozempic could change consumer habitsPopular use of obesity drugs like Ozempic could change consumer habitsRestaurants may face loss of revenue because of the prescription drugs, whereas fitness centers may stand to benefit.
Les mer »

Oh, Ozempic: Retail analysts see little impact from weight-loss drugsOh, Ozempic: Retail analysts see little impact from weight-loss drugsPharmaceutical advocates have hyped the success of high-priced, weight-loss drugs like Ozempic in a campaign to make appetite-suppressing medications a new standard of obesity care, retail analysts say.
Les mer »

Drugs Like Ozempic, Wegovy Linked to Greater Risk of Severe Gastrointestinal Side EffectsDrugs Like Ozempic, Wegovy Linked to Greater Risk of Severe Gastrointestinal Side EffectsNew research links weight loss medications like Ozempic and Wegovy to a greater risk of pancreatitis, gastroparesis, and bowel obstruction. Patients who are losing a more extreme amount of body weight are more at risk for these severe side effects.
Les mer »

What Is Ozempic, the Type 2 Diabetes Medication That Aids Weight Loss?What Is Ozempic, the Type 2 Diabetes Medication That Aids Weight Loss?Turning the calendar page to a new year is often a signal that it’s time for a fresh start. Here are six nutrition plans that could work for you long-term.
Les mer »

Corporate America weighs risks of the Ozempic effectCorporate America weighs risks of the Ozempic effectU.S. companies across sectors such as food and beverage makers and manufacturers of glucose monitors have faced investor questions over the risk to future sales from the growing popularity of promising weight-loss treatments.
Les mer »

Bond Market Noise Masks a Golden Buying OpportunityBond Market Noise Masks a Golden Buying OpportunityBonds Analysis by Michael Lebowitz covering: . Read Michael Lebowitz's latest article on Investing.com
Les mer »



Render Time: 2025-03-01 08:39:52